IL117805A0 - Carbonyl piperazinyl and piperidinyl compounds - Google Patents
Carbonyl piperazinyl and piperidinyl compoundsInfo
- Publication number
- IL117805A0 IL117805A0 IL11780596A IL11780596A IL117805A0 IL 117805 A0 IL117805 A0 IL 117805A0 IL 11780596 A IL11780596 A IL 11780596A IL 11780596 A IL11780596 A IL 11780596A IL 117805 A0 IL117805 A0 IL 117805A0
- Authority
- IL
- Israel
- Prior art keywords
- carbonyl piperazinyl
- piperidinyl
- piperidinyl compounds
- formula
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C07D211/50—Aroyl radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41831995A | 1995-04-07 | 1995-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL117805A0 true IL117805A0 (en) | 1996-08-04 |
Family
ID=23657621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11780596A IL117805A0 (en) | 1995-04-07 | 1996-04-03 | Carbonyl piperazinyl and piperidinyl compounds |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0820452B1 (ja) |
JP (1) | JP3038016B2 (ja) |
AT (1) | ATE242231T1 (ja) |
AU (1) | AU5432696A (ja) |
CA (1) | CA2217351C (ja) |
DE (1) | DE69628559T2 (ja) |
ES (1) | ES2194986T3 (ja) |
IL (1) | IL117805A0 (ja) |
MX (1) | MX9707561A (ja) |
WO (1) | WO1996031501A1 (ja) |
ZA (1) | ZA962694B (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6001835A (en) * | 1996-04-03 | 1999-12-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU707139B2 (en) * | 1996-04-03 | 1999-07-01 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5885995A (en) * | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972942A (en) * | 1997-03-27 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6127390A (en) * | 1997-10-02 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU760434B2 (en) * | 1999-01-14 | 2003-05-15 | Astellas Pharma Inc. | Amide compounds |
AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
CA2362494A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
CA2362493A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2000051547A2 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6376496B1 (en) | 1999-03-03 | 2002-04-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
FR2815032B1 (fr) * | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
GB0119797D0 (en) | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
CA2463626C (en) | 2001-10-17 | 2011-05-24 | Schering Corporation | Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
AR044586A1 (es) * | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
FR2855825B1 (fr) * | 2003-06-04 | 2008-08-22 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
ES2498043T3 (es) * | 2006-06-06 | 2014-09-24 | Cornerstone Therapeutics Inc. | Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
UY30639A1 (es) * | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
EP2132177B1 (en) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
KR20100017866A (ko) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r 억제제, 조성물 및 사용 방법 |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
LT2346495T (lt) | 2008-10-07 | 2016-10-10 | Astrazeneca Uk Limited | Farmacinė kompozicija 514 |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
AR077428A1 (es) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos |
CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
JP2013522292A (ja) | 2010-03-16 | 2013-06-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | インダゾール化合物およびそれらの使用 |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
SG11201802952TA (en) * | 2015-10-09 | 2018-05-30 | Agency Science Tech & Res | Compounds for treatment of cancer and epigenetics |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU675145B2 (en) * | 1993-06-18 | 1997-01-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5576313A (en) * | 1994-08-29 | 1996-11-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5661161A (en) * | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1996
- 1996-04-03 JP JP08530361A patent/JP3038016B2/ja not_active Expired - Fee Related
- 1996-04-03 WO PCT/US1996/004169 patent/WO1996031501A1/en active IP Right Grant
- 1996-04-03 IL IL11780596A patent/IL117805A0/xx unknown
- 1996-04-03 CA CA002217351A patent/CA2217351C/en not_active Expired - Fee Related
- 1996-04-03 ES ES96911440T patent/ES2194986T3/es not_active Expired - Lifetime
- 1996-04-03 AU AU54326/96A patent/AU5432696A/en not_active Abandoned
- 1996-04-03 EP EP96911440A patent/EP0820452B1/en not_active Expired - Lifetime
- 1996-04-03 DE DE69628559T patent/DE69628559T2/de not_active Expired - Fee Related
- 1996-04-03 AT AT96911440T patent/ATE242231T1/de not_active IP Right Cessation
- 1996-04-03 ZA ZA962694A patent/ZA962694B/xx unknown
- 1996-04-03 MX MX9707561A patent/MX9707561A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0820452A1 (en) | 1998-01-28 |
ES2194986T3 (es) | 2003-12-01 |
JP3038016B2 (ja) | 2000-05-08 |
ATE242231T1 (de) | 2003-06-15 |
DE69628559T2 (de) | 2004-04-29 |
ZA962694B (en) | 1996-10-03 |
JPH10511979A (ja) | 1998-11-17 |
WO1996031501A1 (en) | 1996-10-10 |
CA2217351A1 (en) | 1996-10-10 |
CA2217351C (en) | 2003-03-18 |
MX9707561A (es) | 1997-12-31 |
EP0820452B1 (en) | 2003-06-04 |
AU5432696A (en) | 1996-10-23 |
DE69628559D1 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA962694B (en) | Carbonyl piperazinyl and piperidinyl compounds | |
MX9707562A (es) | Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas. | |
IL117782A0 (en) | Tricyclic compounds | |
MY119350A (en) | Propiophenone derivatives and process for preparing the same | |
DE69129193D1 (en) | Triterpenderivat | |
ES2102154T3 (es) | Inhibicion de trombina. | |
PT928788E (pt) | Compostos farmaceuticamente activos | |
AU5551594A (en) | Substituted amino alkyl compounds | |
TW261616B (ja) | ||
IL64314A (en) | 2-oxoazetidine derivatives,their production and antimicrobial and beta-lactamase inhibitory compositions containing them | |
MY143570A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
TW334425B (en) | Annelated dihydropyridines for preparing pharmaceutical preparations | |
DE69734678D1 (de) | 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung | |
CA2293711A1 (en) | Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors | |
CA2127067A1 (fr) | Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2293358A1 (en) | Tricyclic sulfonamide inhibitors of farnesyl-protein transferase | |
AU5176093A (en) | Oleaginous compositions | |
DE69926078D1 (en) | Farnesyl-protein transferase inhibitoren | |
AU3350195A (en) | Bicyclic carboxamides as 5-HT-1A antagonists | |
IL115585A0 (en) | Dipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
MX9706520A (es) | Metodos para inhibir el cancer de ovario. | |
CA2293553A1 (en) | Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase |